ATE424820T1 - Verwendung von pyrrolederivaten gegen angstzustände - Google Patents

Verwendung von pyrrolederivaten gegen angstzustände

Info

Publication number
ATE424820T1
ATE424820T1 AT05028364T AT05028364T ATE424820T1 AT E424820 T1 ATE424820 T1 AT E424820T1 AT 05028364 T AT05028364 T AT 05028364T AT 05028364 T AT05028364 T AT 05028364T AT E424820 T1 ATE424820 T1 AT E424820T1
Authority
AT
Austria
Prior art keywords
pyroleader
compound
isoindolinone
prodrug
chloro
Prior art date
Application number
AT05028364T
Other languages
English (en)
Inventor
Cathyrn Montgomery Clary
Sean David Donevan
Perry Steven Eisman
Richard J Kavoussi
Lyou-Fu Ma
Beek Jeroen Bernard Van
Atul Chandra Pande
Original Assignee
Indevus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indevus Pharmaceuticals Inc filed Critical Indevus Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE424820T1 publication Critical patent/ATE424820T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05028364T 2001-04-30 2002-04-16 Verwendung von pyrrolederivaten gegen angstzustände ATE424820T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28754501P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
ATE424820T1 true ATE424820T1 (de) 2009-03-15

Family

ID=23103396

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02252684T ATE331513T1 (de) 2001-04-30 2002-04-16 Verfahren zur verwendung von pyrrolederivaten gegen zwangsstörungen
AT05028364T ATE424820T1 (de) 2001-04-30 2002-04-16 Verwendung von pyrrolederivaten gegen angstzustände

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02252684T ATE331513T1 (de) 2001-04-30 2002-04-16 Verfahren zur verwendung von pyrrolederivaten gegen zwangsstörungen

Country Status (20)

Country Link
US (2) US7026332B2 (de)
EP (2) EP1642576B1 (de)
JP (1) JP2002326934A (de)
KR (1) KR20020084413A (de)
CN (1) CN1384104A (de)
AT (2) ATE331513T1 (de)
AU (1) AU783516B2 (de)
CA (1) CA2383599C (de)
CY (1) CY1109129T1 (de)
DE (2) DE60231568D1 (de)
DK (1) DK1642576T3 (de)
ES (2) ES2267943T3 (de)
HU (1) HU228826B1 (de)
IL (2) IL149280A0 (de)
MY (1) MY129575A (de)
NZ (1) NZ518615A (de)
PL (2) PL207725B1 (de)
PT (1) PT1642576E (de)
TW (1) TWI302455B (de)
ZA (1) ZA200203347B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502856A (ja) * 2003-05-16 2007-02-15 ファイザー・プロダクツ・インク 精神病性障害および抑うつ性障害の治療
CA2525868A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
DE602004024317D1 (de) * 2003-09-12 2010-01-07 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
KR20060087560A (ko) * 2003-09-12 2006-08-02 워너-램버트 캄파니 엘엘씨 알파-2-델타 리간드 및 ｓｓｒｉ 및/또는 ｓｎｒｉ를포함하는 우울증 및 불안 장애 치료용 조합물
US20050232983A1 (en) * 2004-04-14 2005-10-20 Indevus Pharmaceuticals, Inc. Transdermal patch
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2678337A1 (de) * 2011-02-25 2014-01-01 Concert Pharmaceuticals Inc. 2-amino-naphthyridin-derivate
SG11202109526PA (en) * 2019-03-18 2021-10-28 Neurocycle Therapeutics Inc Use of gabaa receptor modulators for treatment of pain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607503B1 (fr) 1986-12-02 1989-02-24 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
DE3814022A1 (de) * 1988-04-26 1989-11-09 Davy Mckee Ag Verfahren zur herstellung linearer polyester, insbesondere fuer filme und folien
EP0521622B1 (de) 1991-07-03 1997-08-13 PHARMACIA & UPJOHN COMPANY Pyrazolopyrimiden- und Pyrimidinylbisphosphonsäureester als entzündungshemmende Mittel
FR2678934B1 (fr) 1991-07-12 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2678932B1 (fr) 1991-07-12 1993-09-24 Rhone Poulenc Rorer Sa Procede de preparation des isomeres optiques d'un derive de l'amino-2 naphtyridine.
FR2681068B1 (fr) 1991-09-09 1993-11-19 Rhone Poulenc Rorer Sa Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2684673B1 (fr) 1991-12-04 1994-01-21 Rhone Poulenc Rorer Sa Procede de preparation d'un derive de l'amino-2 naphtyridine racemique.
FR2687154B1 (fr) * 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
FR2695389B1 (fr) 1992-09-08 1994-11-04 Rhone Poulenc Rorer Sa Nouveau dérivé de l'isoindolinone, sa préparation et les compositions pharmaceutiques qui le contiennent.
US5498716A (en) * 1994-01-12 1996-03-12 Rhone-Poulenc Rorer S.A. 2-amino naphthyridine derivative, its preparation and its use
GB2305859A (en) * 1996-03-29 1997-04-23 Lilly Co Eli Treatment of obsessive-compulsive disorder
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
WO2001008670A2 (en) * 1999-07-29 2001-02-08 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function

Also Published As

Publication number Publication date
JP2002326934A (ja) 2002-11-15
CA2383599A1 (en) 2002-10-30
PL390683A1 (pl) 2010-05-24
TWI302455B (en) 2008-11-01
DE60231568D1 (de) 2009-04-23
ES2267943T3 (es) 2007-03-16
MY129575A (en) 2007-04-30
PL353681A1 (en) 2002-11-04
DK1642576T3 (da) 2009-04-14
DE60212757D1 (de) 2006-08-10
ES2323646T3 (es) 2009-07-22
HK1094307A1 (en) 2007-03-30
IL204665A (en) 2011-05-31
PL207725B1 (pl) 2011-01-31
CN1384104A (zh) 2002-12-11
AU2760902A (en) 2002-10-31
EP1254660A2 (de) 2002-11-06
US7553847B2 (en) 2009-06-30
PT1642576E (pt) 2009-05-21
EP1254660A3 (de) 2003-03-26
DE60212757T2 (de) 2007-06-28
EP1254660B1 (de) 2006-06-28
US20030022915A1 (en) 2003-01-30
EP1642576A2 (de) 2006-04-05
PL207738B1 (pl) 2011-01-31
US7026332B2 (en) 2006-04-11
US20060128746A1 (en) 2006-06-15
HUP0201394A2 (hu) 2002-12-28
EP1642576A3 (de) 2007-01-10
HUP0201394A3 (en) 2003-12-29
EP1642576B1 (de) 2009-03-11
AU783516B2 (en) 2005-11-03
ATE331513T1 (de) 2006-07-15
NZ518615A (en) 2004-03-26
CA2383599C (en) 2006-10-31
ZA200203347B (en) 2003-11-26
HU0201394D0 (de) 2002-06-29
IL149280A0 (en) 2002-11-10
KR20020084413A (ko) 2002-11-07
HU228826B1 (en) 2013-05-28
CY1109129T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
HUS2100028I1 (hu) ERBB I. típusú receptor tirozinkináz-gátló N4-fenil-kinazolin-4-amin származékok és rokon vegyületeik a hiperproliferatív betegségek kezelésére
DE602004027490D1 (de) Indazol-, benzisoxazol- und benzisothiazol-kinaseinhibitoren
EA200401160A1 (ru) Производные тиазола и оксазола, которые модулируют активность ppar
DE60317198D1 (de) Proteinkinaseinhibitoren
ATE457025T1 (de) Kinaseinhibitoren
CY1107475T1 (el) Αναστολεις ρο-κινασης
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
PA8537501A1 (es) Naftostirilos
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
CY1109129T1 (el) Χρηση παραγωγων πυρρολιου για καταπολεμηση του αγχους
EA200801308A1 (ru) Комбинации, включающие ингибитор cdk и антитело фактора роста, или антимитотик
DE60127537D1 (de) VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE
BRPI0407841A (pt) inibidores heterocìclicos de quinase
ATE277072T1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
EA200600829A1 (ru) Новые кристаллические формы {2-[1-(3,5-бистрифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]-пиридин-3-ил}-(2-хлорфенил)метанона
ATE538784T1 (de) Verfahren zur behandlung von substanzbedingten erkrankungen
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
ECSP066484A (es) Compuestos y metodos para el tratamiento de dislipidemia
DK0674521T3 (da) Fremgangsmåde til behandling af kronisk prostatitis med 17beta-N-tertbutylcarbamoyl-4-aza-5a-andost-1-en-3-on
ATE469887T1 (de) Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz
DK1499312T3 (da) Anvendelse af hydroxypyridonderivater til sårheling
CY1105785T1 (el) Μεθοδοι παρασκευης της 2-(7-χλωρο-1,8-ναφθυριδιν-2-υλ)-3-(5-μεθυλ-2-οξο-εξυλ)-1-ισοϊνδολινονης
FR2827172B1 (fr) Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides
ES2121809T3 (es) N-(3-(2-(1h-imidazol-1-il)etoxi)fenil)-4-(2-tienil)-2-pirimidinamina y sales farmacologicamente aceptables.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1642576

Country of ref document: EP